Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroendocrine Tumors | 3 | 2023 | 651 | 1.160 |
Why?
|
| Rectal Neoplasms | 2 | 2023 | 1239 | 0.880 |
Why?
|
| Colorectal Neoplasms | 8 | 2023 | 3699 | 0.830 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2023 | 98 | 0.820 |
Why?
|
| Somatostatin | 2 | 2019 | 122 | 0.620 |
Why?
|
| Circulating Tumor DNA | 1 | 2020 | 275 | 0.560 |
Why?
|
| Carcinoid Tumor | 1 | 2019 | 278 | 0.550 |
Why?
|
| Colonic Neoplasms | 1 | 2023 | 1427 | 0.490 |
Why?
|
| Intestinal Neoplasms | 1 | 2014 | 199 | 0.410 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 1299 | 0.350 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2014 | 841 | 0.330 |
Why?
|
| Biomarkers, Tumor | 4 | 2020 | 10695 | 0.320 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 16640 | 0.310 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2010 | 668 | 0.290 |
Why?
|
| Pancreatic Neoplasms | 4 | 2014 | 5250 | 0.290 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2012 | 1708 | 0.290 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2023 | 1577 | 0.280 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2010 | 706 | 0.270 |
Why?
|
| Maximum Tolerated Dose | 3 | 2023 | 1320 | 0.270 |
Why?
|
| Sp1 Transcription Factor | 1 | 2006 | 193 | 0.260 |
Why?
|
| Caveolin 1 | 1 | 2006 | 202 | 0.250 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 343 | 0.250 |
Why?
|
| Lung Neoplasms | 3 | 2019 | 12019 | 0.240 |
Why?
|
| Amyloid Precursor Protein Secretases | 3 | 2014 | 101 | 0.230 |
Why?
|
| Cell Differentiation | 1 | 2014 | 4104 | 0.220 |
Why?
|
| Trifluridine | 1 | 2023 | 28 | 0.220 |
Why?
|
| Benzazepines | 2 | 2014 | 116 | 0.210 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2023 | 121 | 0.210 |
Why?
|
| Stomach Neoplasms | 1 | 2014 | 2256 | 0.200 |
Why?
|
| ErbB Receptors | 1 | 2010 | 2376 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2012 | 5405 | 0.170 |
Why?
|
| Liquid Biopsy | 1 | 2020 | 162 | 0.170 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2020 | 218 | 0.170 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2012 | 2388 | 0.170 |
Why?
|
| Adenocarcinoma | 3 | 2014 | 7883 | 0.160 |
Why?
|
| Antineoplastic Agents | 4 | 2014 | 14615 | 0.160 |
Why?
|
| Neoplasms | 2 | 2023 | 15902 | 0.150 |
Why?
|
| Kidney Neoplasms | 1 | 2012 | 3107 | 0.150 |
Why?
|
| Double-Blind Method | 1 | 2023 | 2586 | 0.140 |
Why?
|
| Liver Neoplasms | 2 | 2014 | 4814 | 0.140 |
Why?
|
| Medical Records | 1 | 2019 | 442 | 0.140 |
Why?
|
| Colon | 1 | 2020 | 653 | 0.140 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 417 | 0.140 |
Why?
|
| Everolimus | 1 | 2019 | 436 | 0.130 |
Why?
|
| Camptothecin | 3 | 2014 | 540 | 0.130 |
Why?
|
| Humans | 17 | 2023 | 270033 | 0.120 |
Why?
|
| Signal Transduction | 4 | 2012 | 12087 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 5566 | 0.120 |
Why?
|
| Neoplasm, Residual | 1 | 2020 | 1742 | 0.110 |
Why?
|
| Niacinamide | 2 | 2012 | 428 | 0.110 |
Why?
|
| Embolization, Therapeutic | 1 | 2019 | 605 | 0.110 |
Why?
|
| Radiopharmaceuticals | 1 | 2019 | 1341 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 4958 | 0.110 |
Why?
|
| Benzodioxoles | 1 | 2012 | 29 | 0.100 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2012 | 103 | 0.100 |
Why?
|
| Phenylurea Compounds | 2 | 2012 | 599 | 0.100 |
Why?
|
| 3' Untranslated Regions | 1 | 2012 | 340 | 0.090 |
Why?
|
| Receptor, Notch1 | 1 | 2012 | 216 | 0.090 |
Why?
|
| CA-19-9 Antigen | 1 | 2010 | 154 | 0.090 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 2027 | 0.080 |
Why?
|
| Hydroxamic Acids | 1 | 2012 | 454 | 0.080 |
Why?
|
| Receptors, Notch | 1 | 2012 | 372 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6254 | 0.080 |
Why?
|
| Quality of Life | 1 | 2023 | 4772 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2012 | 617 | 0.070 |
Why?
|
| Disease Progression | 1 | 2019 | 6840 | 0.070 |
Why?
|
| Peritoneal Neoplasms | 1 | 2014 | 855 | 0.070 |
Why?
|
| Quinazolines | 1 | 2012 | 956 | 0.070 |
Why?
|
| Quercetin | 1 | 2006 | 17 | 0.070 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 1327 | 0.070 |
Why?
|
| Oxidants | 1 | 2006 | 50 | 0.070 |
Why?
|
| Middle Aged | 7 | 2019 | 90030 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2014 | 1942 | 0.070 |
Why?
|
| NIH 3T3 Cells | 1 | 2006 | 254 | 0.070 |
Why?
|
| Response Elements | 1 | 2006 | 192 | 0.070 |
Why?
|
| Hydrogen Peroxide | 1 | 2006 | 219 | 0.070 |
Why?
|
| Aged | 6 | 2019 | 73127 | 0.060 |
Why?
|
| Cellular Senescence | 1 | 2006 | 388 | 0.060 |
Why?
|
| Female | 9 | 2019 | 148486 | 0.060 |
Why?
|
| Animals | 5 | 2014 | 61714 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 15172 | 0.060 |
Why?
|
| Antioxidants | 1 | 2006 | 520 | 0.060 |
Why?
|
| Enzyme Activation | 1 | 2006 | 1801 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 9040 | 0.050 |
Why?
|
| United States | 1 | 2020 | 15776 | 0.050 |
Why?
|
| Male | 7 | 2019 | 127917 | 0.050 |
Why?
|
| Cetuximab | 2 | 2014 | 474 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2014 | 4463 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2006 | 2417 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2006 | 1145 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 3842 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 3210 | 0.040 |
Why?
|
| Prognosis | 2 | 2014 | 22451 | 0.040 |
Why?
|
| Gene Dosage | 2 | 2012 | 823 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 3337 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2019 | 33691 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2019 | 39736 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2012 | 14832 | 0.030 |
Why?
|
| Mutation | 2 | 2014 | 15900 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 7779 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 5061 | 0.030 |
Why?
|
| Mice | 3 | 2012 | 35465 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2012 | 3911 | 0.030 |
Why?
|
| Mandibular Neoplasms | 1 | 2013 | 77 | 0.030 |
Why?
|
| Scalp | 1 | 2013 | 155 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 10258 | 0.030 |
Why?
|
| Metastasectomy | 1 | 2014 | 209 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2014 | 409 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2014 | 3398 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2014 | 704 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 589 | 0.020 |
Why?
|
| Survival Rate | 2 | 2014 | 12508 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 892 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2012 | 927 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2012 | 529 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2012 | 488 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2012 | 1012 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2013 | 914 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2012 | 2308 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 3523 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 2472 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 4956 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2012 | 4329 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 30923 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 2013 | 1876 | 0.010 |
Why?
|
| Adult | 3 | 2013 | 81689 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 5138 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2012 | 2887 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 13996 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 4887 | 0.010 |
Why?
|